Last reviewed · How we verify
NCT05601063: ACES
Ascertaining Diagnosis Classification With Elicited Speech
trial testing Winterlight Speech Assessment in Schizophrenia Spectrum and Other Psychotic Disorders in 255 participants. Completed in 1 September 2022.
1 September 2022
Quick facts
| Lead sponsor | Northwell Health |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 255 |
| Start date | 1 October 2020 |
| Primary completion | 1 September 2022 |
| Estimated completion | 1 September 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Winterlight Speech Assessment
Conditions studied
- Schizophrenia Spectrum and Other Psychotic Disorders — all drugs for Schizophrenia Spectrum and Other Psychotic Disorders →
- Bipolar and Related Disorders — all drugs for Bipolar and Related Disorders →
- Depressive Disorder — all drugs for Depressive Disorder →
- Anxiety Disorders — all drugs for Anxiety Disorders →
Sponsor
Northwell Health — full company profile →
Who can join
Adults 14 to 50, any sex, with Schizophrenia Spectrum and Other Psychotic Disorders or Bipolar and Related Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cross-sectional observational study of the relationship between speech patterns and psychiatric symptoms and disorders.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05601063
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia Spectrum and Other Psychotic Disorders
Currently open trials in the same condition.
- NCT06673966 — Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia · recruiting
- NCT06505564 — VR-based Avatar Therapy for Treatment of Auditory Hallucinations · NA · recruiting
- NCT05951660 — Sex, Psychopharmacology, and Diabetes · NA · recruiting
- NCT05877716 — EPI-MINN: Targeting Cognition and Motivation - National · NA · active not recruiting
- NCT05622201 — A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults · Phase 2 · recruiting
Other Northwell Health trials
Trials by the same sponsor.
- NCT07253662 — Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Aden · Phase 1 · recruiting
- NCT07191041 — Emotional Urinary Tract Infection · not yet recruiting
- NCT07254091 — Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer · EARLY_PHASE1 · recruiting
- NCT07344961 — Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB) · recruiting
- NCT07193862 — Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Meta · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05601063 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northwell Health
- Last refreshed: 1 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05601063.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing